

Pharmacy Drug Policy Checklist

POLICY NAME Pyrukynd (mitapivat) POLICY # 3167P

Criteria

Hemolytic Anemia related to Pyruvate Kinase Deficiency (PKD)	
	Diagnosis of hemolytic anemia related to Pyruvate Kinase Deficiency (PKD) as evidenced by genetic testing
	 Genetic testing must support at least two mutant alleles of the PKLR gene of which at least one is a missense mutation
	Age 18 years or older
	Prescribed by or in consultation with a hematologist (blood disorder doctor) or specialist in hemolytic anemia
	Patient has required red blood cell transfusions within the last year
	Hemoglobin level ≤ 10 mg/dL
	Currently taking folic acid 0.8mg daily
Exclusion Criteria – Any of the following prevents coverage	
	Patients homozygous for the R479H mutation
	Patients with 2 non-missense mutations in PKLR, without another missense mutation (these patients did not demonstrate benefit from therapy in clinical trials)